Price
$2.68
Decreased by -0.37%
Dollar volume (20D)
7.45 M
ADR%
5.94
Earnings report date
Feb 26, 2025
Shares float
233.83 M
Shares short
14.07 M [6.02%]
Shares outstanding
335.57 M
Market cap
905.37 M
Beta
1.36
Price/earnings
N/A
20D range
2.51 3.05
50D range
2.09 3.08
200D range
1.67 4.16

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.

The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

The company was founded in 2018 and is headquartered in New York, New York.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 4, 24 -0.15
Decreased by -66.67%
-0.13
Decreased by -15.38%
Aug 5, 24 -0.15
Decreased by -66.67%
-0.06
Decreased by -150.00%
May 14, 24 -0.07
Increased by +30.00%
-0.10
Increased by +30.00%
Feb 29, 24 -0.06
Increased by +40.00%
-0.10
Increased by +40.00%
Nov 2, 23 -0.09
Increased by +25.00%
-0.11
Increased by +18.18%
Aug 3, 23 -0.09
Increased by +43.75%
-0.11
Increased by +18.18%
May 4, 23 -0.10
Increased by 0.00%
-0.10
Mar 15, 23 -0.10
Increased by +16.67%
-0.11
Increased by +9.09%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 727.00 K
Increased by +N/A%
-41.21 M
Decreased by -109.73%
Decreased by -5.67 K%
Decreased by N/A%
Jun 30, 24 1.44 M
Increased by +N/A%
-462.49 M
Decreased by -2.14 K%
Decreased by -32.23 K%
Decreased by N/A%
Mar 31, 24 264.00 K
Increased by +N/A%
-14.79 M
Increased by +12.63%
Decreased by -5.60 K%
Decreased by N/A%
Dec 31, 23 264.00 K
Increased by +N/A%
-13.79 M
Decreased by -85.18%
Decreased by -5.22 K%
Decreased by N/A%
Sep 30, 23 0.00
Increased by +100.00%
-19.65 M
Increased by +21.62%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Increased by +100.00%
-20.64 M
Increased by +35.19%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-16.93 M
Decreased by -17.63%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-7.45 M
Increased by +70.38%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY